Pasithea therapeutics announces completion of enrollment and initial dosing of patients in cohort 6 from its phase 1 trial of pas-004 in advanced cancer patients

Miami, april 29, 2025 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other mapk pathway driven cancer indications, today announced the company has completed enrollment and initial dosing of three subjects in cohort 6 with 30 mg capsules of pas-004.  “we are pleased to have recruited, enrolled and commenced dosing of the initial three subjects in cohort 6 more rapidly than anticipated and we currently expect to complete enrollment of all patients in the trial by the end of 2025,” said dr. tiago reis marques, chief executive officer of pasithea.
KTTA Ratings Summary
KTTA Quant Ranking